{"entity":{"type":"insider","cik":"0001563584","url":"/insider/0001563584","json_url":"/insider/0001563584.json","name":"LEONARD JOHN M","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":67,"n_filings":30,"first":"2013-03-12","last":"2026-08-24","span_basis":"filed_date"},"name_variants":[{"name":"LEONARD JOHN M","source":"filing","n_filings":19,"first_seen":"2020-10-09","last_seen":"2026-08-24"},{"name":"LEONARD JOHN M.","source":"filing","n_filings":11,"first_seen":"2013-03-12","last_seen":"2020-09-03"}],"transactions":[{"id":9300659,"accession":"0001193125-26-363567","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-363567","line_url":"/filing/0001193125-26-363567#line-2","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2785.0,"shares_display":"2,785","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":36205.0,"total_display":"36,205.00","total_whole":"36,205","shares_owned_after":1147064.0,"shares_owned_after_display":"1,147,064","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-21","filed_date":"2026-08-24","scope":"insider"},{"id":9300658,"accession":"0001193125-26-363567","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-363567","line_url":"/filing/0001193125-26-363567#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19890.0,"shares_display":"19,890","price_per_share":12.6,"price_display":"12.60","price_state":"stated","total_value":250614.0,"total_display":"250,614.00","total_whole":"250,614","shares_owned_after":1149849.0,"shares_owned_after_display":"1,149,849","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-20","filed_date":"2026-08-24","scope":"insider"},{"id":5929327,"accession":"0001193125-26-006294","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-006294","line_url":"/filing/0001193125-26-006294#line-1","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34146.0,"shares_display":"34,146","price_per_share":9.21,"price_display":"9.21","price_state":"stated","total_value":314484.66,"total_display":"314,484.66","total_whole":"314,485","shares_owned_after":1013339.0,"shares_owned_after_display":"1,013,339","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-05","filed_date":"2026-01-07","scope":"insider"},{"id":4906690,"accession":"0001193125-25-317551","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-25-317551","line_url":"/filing/0001193125-25-317551","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":88146.0,"shares_display":"88,146","price_per_share":9.488625689197468,"price_display":"9.49","price_state":"stated","total_value":836384.4,"total_display":"836,384.40","total_whole":"836,384","shares_owned_after":1077115.0,"shares_owned_after_display":"1,077,115","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-11","filed_date":"2025-12-12","scope":"insider","n_lines":3},{"id":4909325,"accession":"0000950170-25-003012","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-003012","line_url":"/filing/0000950170-25-003012#line-1","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26807.0,"shares_display":"26,807","price_per_share":12.18,"price_display":"12.18","price_state":"stated","total_value":326509.26,"total_display":"326,509.26","total_whole":"326,509","shares_owned_after":941115.0,"shares_owned_after_display":"941,115","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-03","filed_date":"2025-01-07","scope":"insider"},{"id":2823923,"accession":"0000950170-24-002516","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-002516","line_url":"/filing/0000950170-24-002516#line-1","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19223.0,"shares_display":"19,223","price_per_share":29.46,"price_display":"29.46","price_state":"stated","total_value":566309.58,"total_display":"566,309.58","total_whole":"566,310","shares_owned_after":846486.0,"shares_owned_after_display":"846,486","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-03","filed_date":"2024-01-05","scope":"insider"},{"id":8492828,"accession":"0001209191-23-002425","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-002425","line_url":"/filing/0001209191-23-002425#line-1","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6673.0,"shares_display":"6,673","price_per_share":37.21,"price_display":"37.21","price_state":"stated","total_value":248302.33,"total_display":"248,302.33","total_whole":"248,302","shares_owned_after":766825.0,"shares_owned_after_display":"766,825","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-04","filed_date":"2023-01-06","scope":"insider"},{"id":6424579,"accession":"0001209191-22-016537","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-016537","line_url":"/filing/0001209191-22-016537#line-2","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2493.0,"shares_display":"2,493","price_per_share":112.255,"price_display":"112.26","price_state":"stated","total_value":279851.715,"total_display":"279,851.72","total_whole":"279,852","shares_owned_after":724660.0,"shares_owned_after_display":"724,660","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-01","filed_date":"2022-03-04","scope":"insider"},{"id":4573877,"accession":"0001209191-21-054331","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001209191-21-054331","line_url":"/filing/0001209191-21-054331#line-16","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":44735.0,"shares_display":"44,735","price_per_share":170.0,"price_display":"170.00","price_state":"stated","total_value":7604950.0,"total_display":"7,604,950.00","total_whole":"7,604,950","shares_owned_after":719305.0,"shares_owned_after_display":"719,305","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-01","filed_date":"2021-09-01","scope":"insider"},{"id":4573863,"accession":"0001209191-21-054331","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001209191-21-054331","line_url":"/filing/0001209191-21-054331#line-13","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37833.0,"shares_display":"37,833","price_per_share":155.0,"price_display":"155.00","price_state":"stated","total_value":5864115.0,"total_display":"5,864,115.00","total_whole":"5,864,115","shares_owned_after":719305.0,"shares_owned_after_display":"719,305","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-31","filed_date":"2021-09-01","scope":"insider"},{"id":4573855,"accession":"0001209191-21-054331","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001209191-21-054331","line_url":"/filing/0001209191-21-054331","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":38804.0,"shares_display":"38,804","price_per_share":155.94664055252036,"price_display":"155.95","price_state":"stated","total_value":6051353.44,"total_display":"6,051,353.44","total_whole":"6,051,353","shares_owned_after":730725.0,"shares_owned_after_display":"730,725","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-30","filed_date":"2021-09-01","scope":"insider","n_lines":9},{"id":5202044,"accession":"0001209191-21-053305","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-053305","line_url":"/filing/0001209191-21-053305","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27139.0,"shares_display":"27,139","price_per_share":152.01061792991635,"price_display":"152.01","price_state":"stated","total_value":4125416.16,"total_display":"4,125,416.16","total_whole":"4,125,416","shares_owned_after":727570.0,"shares_owned_after_display":"727,570","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-23","filed_date":"2021-08-25","scope":"insider","n_lines":3},{"id":5477958,"accession":"0001209191-21-052835","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-052835","line_url":"/filing/0001209191-21-052835","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22682.0,"shares_display":"22,682","price_per_share":151.28286482673485,"price_display":"151.28","price_state":"stated","total_value":3431397.94,"total_display":"3,431,397.94","total_whole":"3,431,398","shares_owned_after":732261.0,"shares_owned_after_display":"732,261","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-19","filed_date":"2021-08-20","scope":"insider","n_lines":3},{"id":4178957,"accession":"0001209191-21-024889","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-024889","line_url":"/filing/0001209191-21-024889","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":38209.0,"shares_display":"38,209","price_per_share":83.63634222303645,"price_display":"83.64","price_state":"stated","total_value":3195661.0,"total_display":"3,195,661.00","total_whole":"3,195,661","shares_owned_after":681222.0,"shares_owned_after_display":"681,222","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-01","filed_date":"2021-04-02","scope":"insider","n_lines":2},{"id":4716360,"accession":"0001209191-21-009083","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-009083","line_url":"/filing/0001209191-21-009083#line-6","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28043.0,"shares_display":"28,043","price_per_share":75.0,"price_display":"75.00","price_state":"stated","total_value":2103225.0,"total_display":"2,103,225.00","total_whole":"2,103,225","shares_owned_after":660536.0,"shares_owned_after_display":"660,536","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-09","scope":"insider"},{"id":4716353,"accession":"0001209191-21-009083","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-009083","line_url":"/filing/0001209191-21-009083","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22942.0,"shares_display":"22,942","price_per_share":67.65693487926075,"price_display":"67.66","price_state":"stated","total_value":1552185.4,"total_display":"1,552,185.40","total_whole":"1,552,185","shares_owned_after":632742.0,"shares_owned_after_display":"632,742","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-05","filed_date":"2021-02-09","scope":"insider","n_lines":3},{"id":4258006,"accession":"0001209191-21-007638","txn_seq":20,"anchor":"line-20","filing_url":"/filing/0001209191-21-007638","line_url":"/filing/0001209191-21-007638","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67856.0,"shares_display":"67,856","price_per_share":72.54317967460504,"price_display":"72.54","price_state":"stated","total_value":4922490.0,"total_display":"4,922,490.00","total_whole":"4,922,490","shares_owned_after":614803.0,"shares_owned_after_display":"614,803","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-03","filed_date":"2021-02-03","scope":"insider","n_lines":2},{"id":4257986,"accession":"0001209191-21-007638","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001209191-21-007638","line_url":"/filing/0001209191-21-007638","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":109889.0,"shares_display":"109,889","price_per_share":64.00007898879778,"price_display":"64.00","price_state":"stated","total_value":7032904.68,"total_display":"7,032,904.68","total_whole":"7,032,905","shares_owned_after":532680.0,"shares_owned_after_display":"532,680","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-01","filed_date":"2021-02-03","scope":"insider","n_lines":12},{"id":4552525,"accession":"0001209191-21-001735","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-001735","line_url":"/filing/0001209191-21-001735#line-2","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6239.0,"shares_display":"6,239","price_per_share":55.86,"price_display":"55.86","price_state":"stated","total_value":348510.54,"total_display":"348,510.54","total_whole":"348,511","shares_owned_after":475488.0,"shares_owned_after_display":"475,488","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-05","filed_date":"2021-01-05","scope":"insider"},{"id":2913556,"accession":"0001209191-20-060667","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-060667","line_url":"/filing/0001209191-20-060667","is_derivative":false,"issuer_cik":"0001563584","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001563584","owner_cik":"0001563584","owner_name":"LEONARD JOHN M","owner_display_name":"LEONARD JOHN M","owner_url":"/insider/0001563584","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35000.0,"shares_display":"35,000","price_per_share":38.57142857142857,"price_display":"38.57","price_state":"stated","total_value":1350000.0,"total_display":"1,350,000.00","total_whole":"1,350,000","shares_owned_after":467352.0,"shares_owned_after_display":"467,352","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-27","filed_date":"2020-11-27","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":"2020-11-27|2913551","ledger_fault":false,"count":{"value":67,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":65,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":67},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001652130","name":"Intellia Therapeutics, Inc.","url":"/issuer/0001652130","role":"Director, Officer (President and CEO)","n_filings":24,"first_seen":"2018-05-15","last_seen":"2026-08-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001478242","name":"IQVIA HOLDINGS INC.","url":"/issuer/0001478242","role":"Director","n_filings":1,"first_seen":"2019-12-26","last_seen":"2019-12-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001117480","name":"CHIMERIX INC","url":"/issuer/0001117480","role":"Director","n_filings":3,"first_seen":"2014-11-06","last_seen":"2016-09-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001551152","name":"AbbVie Inc.","url":"/issuer/0001551152","role":"Officer (SVP, Chief Scientific Officer)","n_filings":2,"first_seen":"2013-03-12","last_seen":"2013-03-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001563584","retrieved_at":"2026-08-25T06:37:06+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}